This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Q2 FY27 revenue up 14.9%, profit after tax up 23.8%
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unaudited standalone results for the quarter ended 30 September 2026: revenue was Rs 135.18 crore, up 14.9% year on year from Rs 117.70 crore, and profit after tax was Rs 17.28 crore, up 23.8% from Rs 13.96 crore. Operating earnings before interest, tax, depreciation and amortisation improved from 14.0% to 17.5% of revenue. Standalone half-year operating cash flow was negative Rs 2.16 crore. A first interim dividend of Rs 1 per share was declared.
Positive earnings and the Rs 1 dividend support sentiment, but negative half-year operating cash flow and capital spending are concerns.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹135.2 Cr | ₹117.7 Cr | +14.9% |
| Operating profit | ₹20.08 Cr | ₹14.92 Cr | +34.6% |
| Profit after tax | ₹17.28 Cr | ₹13.96 Cr | +23.8% |
| EBITDA margin | 17.5% | 14.0% | +3.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.